Fig. 6: Birinapant exhibits immune-dependent anti-tumor activity in vivo in a LKB1-mut syngeneic allograft mouse model.

A Schematics of mouse study design. B, C Time course of tumor volume change in immune-competent mice (B, n = 6 mice per group) and immune-deficient nude mice (C, n = 5 mice per group) treated with vehicle control or birinapant (10 mg/kg) as indicated. The data are presented as mean ± SD of the entire experimental cohort. D Representative images from immunohistochemistry (IHC) staining showing 2-doses birinapant-induced increase of tumor infiltrated CD8⁺ T cells in vivo. Tumor samples were collected on Day 6 for the IHC staining analysis. Scale bar: 100 μm. E tSNE plots from single-cell mass cytometry (CyTOF) showing increased tumor infiltrated CD8⁺ T cells upon 2-doses birinapant treatment in vivo. (F) Quantification of tumor-infiltrated CD8⁺ T cells from single-cell CyTOF profiling. The data are expressed as the percentage of CD8⁺ T cells in the live cell population. Each data point represents individual samples from immune-competent mice. (n = 5 mice for vehicle group, n = 7 mice for birinapant group). G Immunoblot showing birinapant-induced STING expression in vivo. Tumor samples harvested from the immune-competent mice at the endpoint were analyzed by SDS-PAGE and western blot with indicated antibodies. One representative blot of n = 3 biological replicates. Source data are provided as a Source Data file. For (B, C, and F), data are presented as mean values ± SD. P-values were calculated by unpaired Student’s t test with two-tailed analysis without adjustments.